MEI Pharma Dirección
Dirección controles de criterios 2/4
El CEO de MEI Pharma's es David Urso , nombrado en Jun 2023, tiene una permanencia de menos de un año. compensación anual total es $2.10M, compuesta por 25.8% salario y 74.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.037% de las acciones de la empresa, por valor de $8.30K. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 3.5 años, respectivamente.
Información clave
David Urso
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 25.8% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | 1.5yrs |
| Promedio de permanencia en la Junta Directiva | 3.5yrs |
Actualizaciones recientes de la dirección
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 17
Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)
Dec 30Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)
Nov 19We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022
Mar 26Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts
Feb 12MEI Pharma: Another PI3K Delta Progressing To The FDA
Feb 01Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates
Dec 02We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04MEI Pharma EPS misses by $0.12, misses on revenue
May 06MEI Pharma promotes Richard Ghalie to chief medical officer
Apr 30MEI Pharma shares rise 4% as Wells Fargo says voruciclib undervalued
Apr 26The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 11
MEI Pharma EPS beats by $0.01, beats on revenue
Feb 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$20m |
| Sep 30 2023 | n/a | n/a | US$41m |
| Jun 30 2023 | US$2m | US$541k | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | US$2m | US$517k | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | n/a | n/a | -US$64m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | US$2m | US$492k | -US$41m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | n/a | n/a | -US$31m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | US$1m | US$460k | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | n/a | n/a | -US$38m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | US$1m | US$426k | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | n/a | n/a | -US$28m |
| Sep 30 2018 | n/a | n/a | -US$46m |
| Jun 30 2018 | US$1m | US$390k | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$25m |
| Dec 31 2017 | n/a | n/a | -US$20m |
| Sep 30 2017 | n/a | n/a | -US$2m |
| Jun 30 2017 | US$671k | US$375k | US$3m |
Compensación vs. Mercado: La compensación total de David($USD2.10M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).
Compensación vs. Ingresos: La compensación de David ha sido consistente con los resultados de la empresa en el último año.
CEO
David Urso (59 yo)
less than a year
Permanencia
US$2,101,058
Compensación
Mr. David M. Urso, Esq., JD, serves as Chief Executive Officer and President at MEI Pharma, Inc. since June 2, 2023 and had been its Senior Vice President of Corporate Development from March 2014 to July 1...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.10m | 0.037% $ 7.6k | |
| Chief Medical Officer | 8.1yrs | US$846.66k | 0.022% $ 4.5k | |
| CFO & Corporate Secretary | less than a year | sin datos | sin datos | |
| Senior Vice President of Operations & Quality | less than a year | sin datos | sin datos | |
| Vice President of Legal Affairs | 1.3yrs | sin datos | sin datos | |
| Chief People Officer | 1.8yrs | sin datos | sin datos | |
| Strategic Advisor | 12.8yrs | US$755.98k | 0% $ 0 | |
| Senior Vice President of Corporate Affairs | 2.9yrs | sin datos | sin datos |
1.5yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MEIP no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.10m | 0.037% $ 7.6k | |
| Independent Non-Executive Director | 6.2yrs | US$99.20k | 0.028% $ 5.8k | |
| Independent Non-Executive Director | 10.8yrs | US$111.20k | 0% $ 0 | |
| Independent Non-Executive Director | 11.2yrs | US$144.60k | 0.0075% $ 1.5k | |
| Independent Non-Executive Chair | 12.5yrs | US$119.20k | 0.083% $ 17.2k | |
| Independent Non-Executive Director | less than a year | sin datos | 0.019% $ 3.9k | |
| Independent Director | less than a year | sin datos | sin datos | |
| Director | less than a year | sin datos | sin datos |
3.5yrs
Permanencia media
56.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MEIP se considera experimentada (3.5 años de antigüedad promedio).